Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line

Chemistry and Biology

Volumn 10, Issue 9, 2003, Pages 837-846

  Liu, Yichin ^a,b,c   Lashuel, Hilal A ^a,b,c   Choi, Sungwoon ^c,d   Xing, Xuechao ^c,d   Case, April ^c,d   Ni, Jake ^c,d   Yeh, Li An ^c,d   Cuny, Gregory D ^c,d   Stein, Ross L ^a,b,c,d   Lansbury Jr , Peter T ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c The Harvard Center for Neurodegeneration & Repair   (United States)

^d Lab Drug Discov Neurodegeneration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12444269118     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2003.08.010     Document Type: Article

References (41)

1. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 246:1989;670-673.
2. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T.et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
3. Larsen C.N., Price J.S., Wilkinson K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases. identification of two active site residues Biochemistry. 35:1996;6735-6744.
4. Larsen C.N., Krantz B.A., Wilkinson K.D. Substrate specificity of deubiquitinating enzymes. ubiquitin C-terminal hydrolases Biochemistry. 37:1998;3358-3368.
5. Wilkinson K.D. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. 11:1997;1245-1256.
6. Dang L.C., Melandri F.D., Stein R.L. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry. 37:1998;1868-1879.
7. Chung C.H., Baek S.H. Deubiquitinating enzymes. their diversity and emerging roles Biochem. Biophys. Res. Commun. 266:1999;633-640.
8. Kurihara L.J., Kikuchi T., Wada K., Tilghman S.M. Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum. Mol. Genet. 10:2001;1963-1970.
9. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218.
10. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 53:1999;1858-1860.
11. Levecque C., Destee A., Mouroux V., Becquet E., Defebvre L., Amouyel P., Chartier-Harlin M.C. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J. Neural Transm. 108:2001;979-984.
12. Satoh J.I., Kuroda Y. Ubiquitin C-terminal hydrolase-L1 (PGP9.5) expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines, neurotrophic factors or heat stress. Neuropathol. Appl. Neurobiol. 27:2001;95-104.
13. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51:2002;133-136.
14. Wang J., Zhao C.Y., Si Y.M., Liu Z.L., Chen B., Yu L. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov. Disord. 17:2002;767-771.
15. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Correze J.R., Delemotte B., Amouyel P., Alperovitch A., Chartier-Harlin M.C.et al. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease. evidence for an age-dependent relationship Mov. Disord. 18:2003;130-137.
16. Caballero O.L., Resto V., Patturajan M., Meerzaman D., Guo M.Z., Engles J., Yochem R., Ratovitski E., Sidransky D., Jen J. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene. 21:2002;3003-3010.
17. Sasaki H., Yukiue H., Moriyama S., Kobayashi Y., Nakashima Y., Kaji M., Fukai I., Kiriyama M., Yamakawa Y., Fujii Y. Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn. J. Clin. Oncol. 31:2001;532-535.
18. Bittencourt Rosas S.L., Caballero O.L., Dong S.M., da Costa Carvalho Mda G., Sidransky D., Jen J. Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett. 170:2001;73-79.
19. Hibi K., Westra W.H., Borges M., Goodman S., Sidransky D., Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am. J. Pathol. 155:1999;711-715.
20. Hibi K., Liu Q., Beaudry G.A., Madden S.L., Westra W.H., Wehage S.L., Yang S.C., Heitmiller R.F., Bertelsen A.H., Sidransky D.et al. Serial analysis of gene expression in non-small cell lung cancer. Cancer Res. 58:1998;5690-5694.
21. Sunday M.E., Willett C.G., Graham S.A., Oreffo V.I., Linnoila R.I., Witschi H. Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone with or without hyperoxia. Am. J. Pathol. 147:1995;740-752.
22. Yamazaki T., Hibi K., Takase T., Tezel E., Nakayama H., Kasai Y., Ito K., Akiyama S., Nagasaka T., Nakao A. PGP9.5 as a marker for invasive colorectal cancer. Clin. Cancer Res. 8:2002;192-195.
23. Grozinger C.M., Schreiber S.L. Deacetylase enzymes. biological functions and the use of small-molecule inhibitors Chem. Biol. 9:2002;3-16.
24. Haggarty S.J., Mayer T.U., Miyamoto D.T., Fathi R., King R.W., Mitchison T.J., Schreiber S.L. Dissecting cellular processes using small molecules. identification of colchicine-like, taxol-like and other small molecules that perturb mitosis Chem. Biol. 7:2000;275-286.
25. Johnston S.C., Riddle S.M., Cohen R.E., Hill C.P. Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J. 18:1999;3877-3887.
26. Melandri F., Grenier L., Plamondon L., Huskey W.P., Stein R.L. Kinetic studies on the inhibition of isopeptidase T by ubiquitin aldehyde. Biochemistry. 35:1996;12893-12900.
27. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:1999;67-73.
28. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26.
29. Gaeta, F., Galan, A.A., and Kraynack, E.A. (December 1999). Telomerase inhibitors. WO 99/65875.
30. Jensen, B.S., Jørgensen, T.D., Ahring, P.K., Christophersen, P., Strøbæk, D., Teuber, L., and Olesen, S.P. (June 2000). Use of isatine derivatives as Ion channel activating agents. WO 00/33834.
31. Wätjen, F., Drejer, J., and Jensen, L.H. (March 1993). Isatine derivatives, their preparation and use. U.S. patent 5,198,461.
32. Salituro, F.G., Bemis, G.W., Wilke, S., Green, J., Cao, J., Gao, H., and Harrington, E.M. (November 2000). Inhibitors of c-Jun N-terminal kinases (JNK). WO 00/64872.
33. Al-Katib A.M., Mohammad R.M., Maki A., Smith M.R. Induced expression of a ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia. Cell Growth Differ. 6:1995;211-217.
34. Maki A., Mohammad R.M., Smith M., Al-Katib A. Role of ubiquitin carboxyl terminal hydrolase in the differentiation of human acute lymphoblastic leukemia cell line, Reh. Differentiation. 60:1996;59-66.
35. Miura H., Oda K., Endo C., Yamazaki K., Shibasaki H., Kikuchi T. Progressive degeneration of motor nerve terminals in GAD mutant mouse with hereditary sensory axonopathy. Neuropathol. Appl. Neurobiol. 19:1993;41-51.
36. Mukoyama M., Yamazaki K., Kikuchi T., Tomita T. Neuropathology of gracile axonal dystrophy (GAD) mouse. An animal model of central distal axonopathy in primary sensory neurons. Acta Neuropathol. 79:1989;294-299.
37. Oda K., Yamazaki K., Miura H., Shibasaki H., Kikuchi T. Dying back type axonal degeneration of sensory nerve terminals in muscle spindles of the gracile axonal dystrophy (GAD) mutant mouse. Neuropathol. Appl. Neurobiol. 18:1992;265-281.
38. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T.et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23:1999;47-51.
39. Wu J., Ichihara N., Chui D.H., Yamazaki K., Kikuchi T. Ubiquitin immunoreactivity in the central nervous system of gracile axonal dystrophy (GAD) mouse. No To Shinkei. 47:1995;881-885.
40. Moss A., Blackburn-Munro G., Garry E.M., Blakemore J.A., Dickinson T., Rosie R., Mitchell R., Fleetwood-Walker S.M. A role of the ubiquitin-proteasome system in neuropathic pain. J. Neurosci. 22:2002;1363-1372.
41. Tezel E., Hibi K., Nagasaka T., Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin. Cancer Res. 6:2000;4764-4767.